Rosen Law Firm Urges AstraZeneca Investors to Act Before Upcoming Deadline in Class Action Lawsuit

New York, New York--(December 30, 2024) - Introduction: Rosen Law Firm, recognized as a leading global investor rights law firm, has initiated a class action lawsuit on behalf of investors who purchased securities of AstraZeneca PLC (NASDAQ: LON) between February 23, 2022, and December 17, 2024 (the "Class Period"). This lawsuit has already been filed. If you are interested in becoming the lead plaintiff, it is vital to act before the deadline on February 21, 2025.

Reason for Action: Investors who bought AstraZeneca securities during the Class Period may have the right to claim compensation without incurring any out-of-pocket costs, thanks to a contingency fee arrangement.

Next Steps: To join the AstraZeneca class action, you can visit this link or call Phillip Kim, Esq. toll-free at 866-767-3653. You can also reach out via email at [email protected]. It is crucial to note that a class action lawsuit has been initiated, and if you wish to serve as the lead plaintiff, you must file your motion with the Court by February 21, 2025. The lead plaintiff represents all class members and guides the litigation process.

Why Choose Rosen Law Firm?: Selecting experienced legal counsel is essential. Rosen Law Firm is known for its track record of successful class action settlements, setting industry standards. The firm has achieved notable accomplishments, such as negotiating the largest securities class action settlement against a Chinese company at the time. According to ISS Securities Class Action Services, Rosen Law Firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top four since 2013, returning hundreds of millions to investors—over $438 million in 2019 alone. Highlighted by law360, founding partner Laurence Rosen has earned recognition as a Titan of Plaintiffs' Bar, with various attorneys at the firm gaining accolades from Lawdragon and Super Lawyers.

Case Details: The class action lawsuit asserts that AstraZeneca made several materially false statements during the Class Period. Allegations include that AstraZeneca engaged in insurance fraud in China, which led to increased legal risks and the detention of AstraZeneca’s President in that country. It is claimed that the company understated its legal concerns, and once these issues were publicly disclosed, AstraZeneca's business operations in China could be severely impacted. These revelations reportedly caused financial harm to the investors, as stated in the lawsuit.

For those wanting to join the AstraZeneca class action, please refer to the contact link, or you can reach out to Phillip Kim, Esq. toll-free at 866-767-3653 or via email at [email protected].

No class has been certified yet. Until then, you are not represented by any counsel unless you choose to retain one. You may opt to select your attorney or remain an absent class member, as your ability to potentially recover does not depend on being the lead plaintiff.

For further updates, follow Rosen Law Firm on LinkedIn, Twitter, or Facebook.

Disclaimer: Attorney Advertising. Previous results do not guarantee a similar outcome.

AstraZeneca, lawsuit, investors